Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

KA34 to enter clinical testing for the treatment of osteoarthritis

Jan. 11, 2018

Galapagos reports topline results from phase Ib study of GLPG-1972 in osteoarthritis

Jan. 9, 2018

BioCryst Pharmaceuticals begins IND-enabling studies of two lead candidates

Jan. 9, 2018

Galapagos and Servier report ADAMTS inhibitors for osteoarthritis

Jan. 2, 2018

Patient recruitment ongoing in phase II trial of CR-6086

Dec. 29, 2017

Clover Biopharmaceuticals receives approval to initiate clinical trials of SCB-808 in China

Dec. 28, 2017

Phase II study of anabasum in SLE begins

Dec. 27, 2017

UCB reports phase IIb data on bimekizumab in psoriatic arthritis

Dec. 21, 2017

AbbVie reports topline results from phase III study of upadacitinib

Dec. 21, 2017

Fresenius submits first biosimilar MAA to EMA

Dec. 19, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 24, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
In the clinic for June 22, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...
K2 nabs two Antengene bispecific TCEs in $2B license, option deal
BioWorld
MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene...